UMMS Affiliation

Department of Surgery; Department of Radiology; Department of Radiation Oncology; Department of Pathology

Publication Date

2020-04-09

Document Type

Article

Disciplines

Digestive System Diseases | Neoplasms | Oncology | Pathological Conditions, Signs and Symptoms | Radiation Medicine | Radiology

Abstract

Purpose: Our purpose was to report outcomes in patients with Child-Pugh B or C (CP B/C) hepatocellular carcinoma (HCC) treated with stereotactic body radiation therapy (SBRT).

Methods and Materials: Patients with HCC suitable for SBRT were prospectively enrolled in the study from 2012 to 2018. Outcomes in patients with CP B/C were analyzed. Cox proportional hazard models were used to compare survival outcomes between baseline CP score and post-SBRT CP score.

Results: Twenty-three patients with CP B/C with a total of 29 HCC tumors were treated with SBRT. Eighty-seven percent of patients were CP B8-C10. Median tumor size was 3.1 cm (range, 1-10 cm). Median dose delivered was 40 Gy in a median of 5 fractions. Eighteen of 23 patients (78.3%) had been previously treated with transarterial chemoembolization. Median follow-up was 14.5 months. Rates of 6- and 12-month local control were 100% and 92.3%, respectively. Six- and 12-month survival rates were 73.9% and 56.5%, respectively. Median survival was 14.5 months overall and 9.2, 22.5, 14.5, and 14.4 months for patients with CP B7, B8, B9, and C10, respectively. No patients exhibited symptoms of classic radiation-induced liver disease. However, 10 patients had CP score progression, with 4 patients (17%) having a > /=2-point increase in CP score by 6 months (or time of censor). There were 7 liver-related deaths, and based on independent review by a hepatologist, 1 of these deaths may have been attributable to SBRT-related liver injury. Fifteen of 23 patients were listed for liver transplant (LT) at the time of SBRT and 9 went on to receive LT with a pathologic complete response rate of 63.6%. Median survival, excluding patients who received LT, was 7.3 months.

Conclusions: SBRT is a reasonable treatment option for carefully selected patients with CP B7-C10. In our small cohort, there was no detectable difference between local control or overall survival and baseline CP score.

Keywords

hepatocellular carcinoma, stereotactic body radiation therapy, child-pugh, cirrhosis

Rights and Permissions

Copyright 2020 The Author(s). Published by Elsevier Inc. on behalf of American Society for Radiation Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

DOI of Published Version

10.1016/j.adro.2020.01.009

Source

Lee P, Ma Y, Zacharias I, Bozorgzadeh A, Wilson S, Foley K, Rava P, Masciocchi M, Ding L, Bledsoe J, Fitzgerald TJ, Sioshansi S. Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma in Patients With Child-Pugh B or C Cirrhosis. Adv Radiat Oncol. 2020 Apr 9;5(5):889-896. doi: 10.1016/j.adro.2020.01.009. PMID: 33083650; PMCID: PMC7557134. Link to article on publisher's site

Journal/Book/Conference Title

Advances in radiation oncology

Related Resources

Link to Article in PubMed

PubMed ID

33083650

Creative Commons License

Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.

Share

COinS